CytomX Therapeutics, Inc. (CTMX) - 10-K Summary
Business Context and Reporting Period
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company developing conditionally activated, masked biologics using its proprietary PROBODY platform. The company has no approved products and generates revenue primarily through collaboration agreements. This report covers the fiscal year ended December 31, 2025.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Total Revenue | $76.2 million | $138.1 million |
| Net Loss | $(17.4) million | $31.9 million (Net Income) |
| Research & Development Expenses | $68.7 million | $83.4 million |
| General & Administrative Expenses | $29.8 million | $29.7 million |
| Cash, Cash Equivalents & Short-Term Investments | $137.1 million | $100.6 million |
| Accumulated Deficit | $(711.9) million | $(691.6) million |
Note: The company reported a net loss in 2025 compared to net income in 2024. Revenue declined significantly due to the completion of performance obligations under major collaboration agreements.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by $61.9 million (45%) year-over-year. This was primarily driven by the completion of performance obligations under the Bristol Myers Squibb (BMS) agreement in Q2 2025 and a pause in activities under the Moderna agreement due to the partner's budget considerations.
- Restructuring: In January 2025, the company executed a restructuring plan reducing its workforce by approximately 40% to preserve capital. This resulted in $2.8 million in restructuring charges ($1.7 million in R&D and $1.1 million in G&A).
- Capital Raise: In May 2025, the company completed an underwritten public offering raising approximately $93.4 million in net proceeds. Additionally, $16.3 million was raised via its At-The-Market (ATM) program.
- Collaboration Terminations: The collaboration with Amgen regarding the EGFR product (CX-904) was terminated in March 2025. In March 2026 (subsequent event), Astellas notified the company of the termination of its collaboration, effective Q2 2026.
Guidance, Outlook, and Risks
Outlook: Management expects existing capital resources ($137.1 million as of Dec 31, 2025) to fund operations into the second quarter of 2027. The company is prioritizing its two lead clinical programs: Varseta-M and CX-801.
Clinical Updates:
- Varseta-M (EpCAM ADC): Phase 1 dose expansion data (Jan 2026 cutoff) showed a confirmed overall response rate (cORR) of 32% at the 10 mg/kg dose in late-line metastatic colorectal cancer (CRC). The company aims to align with the FDA in 2026 on a registrational study design.
- CX-801 (Masked Interferon-alpha): Phase 1 monotherapy data presented in Nov 2025 demonstrated the mechanism of action was working as designed. Combination studies with KEYTRUDA are ongoing.
Risks and Contingencies:
- Liquidity: The company has a history of losses and will require substantial additional funding to advance development. Failure to secure capital could force delays or terminations of programs.
- Collaboration Dependency: Revenue is heavily dependent on milestone payments and research fees from partners. Recent terminations (Amgen, Astellas) and pauses (Moderna) highlight the risk of revenue volatility.
- Manufacturing: The company relies on third-party manufacturers, including sole-source suppliers in China and Europe, creating supply chain risks.
- Regulatory: As a clinical-stage company, there is no guarantee of regulatory approval for any product candidates.
Key Facts for Investor Verification
- Verify the timeline and terms of the upcoming registrational study for Varseta-M in late-line CRC.
- Monitor the status of the Astellas collaboration termination and the company's plan to advance any remaining targets internally.
- Assess the impact of the Moderna collaboration pause on future revenue recognition and deferred revenue balances.
- Review the company's cash burn rate relative to the projected runway into Q2 2027.
- Confirm the safety profile of Varseta-M, specifically regarding the management of diarrhea and the single Grade 5 acute kidney injury event reported in 2025.